Topical Trametinib for Agminated Spitz Nevi Harboring HRAS Mutation
Document Type
Journal Article
Publication Date
2-19-2025
Journal
Pediatric dermatology
DOI
10.1111/pde.15903
Keywords
agminated spitz nevus; dermatology; male; nevus spilus; skin diseases
Abstract
The treatment of agminated Spitz nevi can be challenging due to the potential for disfigurement in cosmetically sensitive areas. We report the case of a pediatric patient with progressive agminated Spitz nevi arising from a nevus spilus on the face with an associated pathogenic HRAS p.G13R mutation revealed on next-generation sequencing (NGS). The patient was treated with compounded topical trametinib 1% cream and demonstrated significant clinical improvement following 12 weeks of twice-daily treatment. Our case highlights the potential role of MEK inhibition as a targeted, non-surgical treatment for HRAS-mutated agminated Spitz nevi and adds to the growing understanding of their genetic etiology.
APA Citation
Parsons, Lauren; Chen, Alice; Bertus, Brooke; Beatty, Colleen; Stashower, Julian; Tomboc, Patrick; Brooke, Sebastian; and Zinn, Zachary, "Topical Trametinib for Agminated Spitz Nevi Harboring HRAS Mutation" (2025). GW Authored Works. Paper 6551.
https://hsrc.himmelfarb.gwu.edu/gwhpubs/6551
Department
School of Medicine and Health Sciences Student Works